The term “myeloablative megatherapy” describes a strategy of anticancer chemotherapy, in which the dose of drugs is increased to the extent that myelosuppression as a side effect will not recover by itself. To restore the patient’s hematopoiesis, his own blood stem cells are harvested and frozen before the high-dose chemotherapy and thawed and reinfused thereafter.
The alternative to autologous stem cell transplantation is allogenic stem cell transplantation; this means that a healthy donor provides the cells to restore the patient’s hematopoiesis.
Anticancer drugs are not dosed according to maximal damage to the cancer cell, but to keep their toxicity within limits tolerable for the patient. The amount which can safely be given is usually less than that which would exhaust the drug’s potential...